Your browser is no longer supported. Please, upgrade your browser.
Settings
ACRX AcelRx Pharmaceuticals, Inc. daily Stock Chart
ACRX [NASD]
AcelRx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.63 Insider Own0.90% Shs Outstand44.43M Perf Week-2.49%
Market Cap156.39M Forward P/E- EPS next Y-0.86 Insider Trans-59.12% Shs Float43.57M Perf Month-4.61%
Income-27.70M PEG- EPS next Q-0.10 Inst Own71.20% Short Float8.90% Perf Quarter-27.27%
Sales17.80M P/S8.79 EPS this Y-30.50% Inst Trans1.43% Short Ratio7.42 Perf Half Y-19.45%
Book/sh0.90 P/B3.91 EPS next Y-104.80% ROA-30.90% Target Price7.30 Perf Year-49.64%
Cash/sh2.35 P/C1.50 EPS next 5Y- ROE-68.50% 52W Range2.59 - 9.32 Perf YTD-8.57%
Dividend- P/FCF- EPS past 5Y5.80% ROI-52.70% 52W High-62.23% Beta2.27
Dividend %- Quick Ratio15.50 Sales past 5Y- Gross Margin- 52W Low35.91% ATR0.31
Employees50 Current Ratio15.50 Sales Q/Q220.80% Oper. Margin- RSI (14)48.33 Volatility7.02% 11.03%
OptionableYes Debt/Eq0.52 EPS Q/Q450.00% Profit Margin- Rel Volume0.33 Prev Close3.59
ShortableYes LT Debt/Eq0.52 EarningsMar 07 AMC Payout- Avg Volume522.75K Price3.52
Recom2.20 SMA206.88% SMA50-12.67% SMA200-12.23% Volume175,668 Change-1.95%
Oct-30-15Upgrade Jefferies Hold → Buy
Oct-05-15Reiterated ROTH Capital Buy $8.50 → $10.50
Sep-02-15Initiated H.C. Wainwright Buy $8.50
Jul-10-15Resumed ROTH Capital Buy $7.50
May-06-15Reiterated Mizuho Neutral $5.50 → $3
May-05-15Reiterated RBC Capital Mkts Outperform $8 → $7
Mar-10-15Reiterated RBC Capital Mkts Outperform $12 → $8
Mar-09-15Downgrade Mizuho Buy → Neutral $14 → $5.59
Feb-26-15Upgrade Mizuho Neutral → Buy $6 → $14
Nov-06-14Downgrade Mizuho Buy → Neutral $15 → $6
Sep-26-14Downgrade ROTH Capital Buy → Neutral
Jul-28-14Reiterated RBC Capital Mkts Outperform $15 → $12
Jul-28-14Reiterated Mizuho Buy $20 → $15
Jul-28-14Downgrade Canaccord Genuity Buy → Hold
Apr-17-14Initiated Canaccord Genuity Buy $16
Jan-07-14Initiated RBC Capital Mkts Outperform $15
Dec-19-13Reiterated Mizuho Buy $18 → $20
Dec-17-13Reiterated MLV & Co Buy $15 → $16.50
Jul-17-13Reiterated Mizuho Neutral $13 → $18
Feb-04-13Initiated MLV & Co Buy $13
Feb-03-16 07:00AM  AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in February PR Newswire
Jan-21-16 07:00AM  AcelRx Pharmaceuticals Announces Presentation of Phase 3 Sufentanil Sublingual 30 mcg Tablet (ARX-04) Data at the European Congress of Ambulatory Surgery PR Newswire +7.58%
Jan-11-16 10:04AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosur -8.72%
Jan-10-16 07:00AM  AcelRx Pharmaceuticals Announces Anticipated 2016 Milestones PR Newswire
Jan-08-16 07:02AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  AcelRx Completes Protocol Review with FDA and Plans to Initiate Phase 3 Open-Label Study (IAP312) for Zalviso in 1Q 2016 PR Newswire
Dec-23-15 07:00AM  AcelRx Pharmaceuticals Receives Notice of Eligibility for Centralized Review of ARX-04 from European Medicines Agency PR Newswire
Dec-14-15 01:50PM  AcelRx Tanks on Pre-NDA Results -20.39%
07:02AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  AcelRx Pharmaceuticals Conducts Pre-NDA Meeting with U.S. Food and Drug Administration for ARX-04 PR Newswire
Dec-08-15 01:16PM  ACELRX PHARMACEUTICALS INC Financials
11:39AM  Should You Avoid AcelRx Pharmaceuticals Inc (ACRX)? at Insider Monkey
Nov-27-15 03:19PM  Abraxas Petroleum Corp. (AXAS): Are Hedge Funds Right About This Stock? at Insider Monkey
Nov-23-15 07:00AM  AcelRx Pharmaceuticals to Present at Piper Jaffray 27th Annual Healthcare Conference PR Newswire +7.06%
Nov-19-15 08:50AM  A Look at Equity Market Momentum - Research on Multi-Fineline Electronix, AcelRx Pharmaceuticals, CAI International and Peregrine Pharmaceuticals Accesswire
07:09AM  AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentation at the American Society of Regional Anesthesia and Pain Medicine Meeting
07:00AM  AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentation at the American Society of Regional Anesthesia and Pain Medicine Meeting PR Newswire
Nov-10-15 07:00AM  AcelRx Pharmaceuticals to Present at Jefferies 2015 Global Healthcare Conference PR Newswire
Nov-05-15 07:00AM  AcelRx Pharmaceuticals to Present at Credit Suisse 24th Annual Healthcare Conference PR Newswire -5.99%
Nov-04-15 07:00AM  AcelRx Pharmaceuticals Presents Data from Phase 3 Clinical Trials Evaluating the Safety and Efficacy of Zalviso in Obese Surgical Patients PR Newswire +7.08%
Nov-03-15 06:09AM  ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Nov-02-15 06:55AM  Where Opportunity is Found - Research on AcelRx Pharmaceuticals, Tandem Diabetes Care, Brightcove and SciQuest Accesswire +11.17%
06:07AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Oct-30-15 09:24PM  Edited Transcript of ACRX earnings conference call or presentation 29-Oct-15 8:30pm GMT +17.61%
01:25PM  5 Analyst Upgrades That Were Too Big to Ignore at 24/7 Wall St.
Oct-29-15 05:29PM  AcelRx Pharmaceuticals tops Street 3Q forecasts
04:30PM  AcelRx Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:10PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
04:01PM  AcelRx Pharmaceuticals Provides Business Update and Reports Third Quarter and Nine Months 2015 Financial Results PR Newswire
07:07AM  Q3 2015 AcelRx Pharmaceuticals Inc Earnings Release - After Market Close
Oct-26-15 07:00AM  AcelRx Pharmaceuticals to Hold Business Update and Third Quarter Financial Results Conference Call and Webcast on Thursday, Oct 29th, 2015 PR Newswire
Oct-23-15 07:00AM  AcelRx Pharmaceuticals Announces Presentation Of Phase 3 Data From ARX-04 Sufentanil Sublingual 30 mcg Program At The American Society Of Anesthesiology Meeting PR Newswire
Oct-09-15 12:08PM  IMMU and ACRX Outperform in the Biotech Downdraft
07:00AM  AcelRX Pharmaceuticals Announces Presentation Of Phase 3 Sufentanil Sublingual 30mcg Tablet Data At The European Society Of Emergency Medicine Meeting PR Newswire
Oct-08-15 05:00PM  AcelRx Updates on Zalviso for Pain Management Treatment -5.45%
07:01AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  AcelRx Pharmaceuticals Provides Regulatory Update on Zalviso PR Newswire
Oct-06-15 07:00AM  AcelRx Pharmaceuticals Announces Initiation of Clinical Study with ARX-04 in Emergency Room Patients with Moderate-to-Severe Acute Pain PR Newswire
Oct-02-15 05:23PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +9.06%
10:43AM  Amicus, Other Biotech CEOs Should Listen More, Talk Less About FDA Matters at TheStreet
Oct-01-15 11:07AM  AcelRx Pharmaceuticals, Inc. Earnings Q2, 2015
09:30AM  New Strong Buy Stocks for October 1st
08:22AM  AcelRx Pharmaceuticals (ACRX) Enters Oversold Territory
07:00AM  AcelRx Pharmaceuticals Appoints Gina Ford as Vice President Commercial Strategy PR Newswire
Sep-29-15 09:30AM  New Strong Buy Stocks for September 29th
Sep-24-15 03:25PM  PDL BioPharma Concludes Financing Agreement with Avinger
07:00AM  AcelRx Pharmaceuticals to Host Analyst & Investor Event on October 2, 2015 PR Newswire
Sep-23-15 04:00PM  AcelRx's Pain Treatment Drug Zalviso Approved in Europe
Sep-22-15 05:58PM  PDL BioPharma to Get Royalties on AcelRx's Zalviso Sales
02:57PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:41AM  AcelRx Pharmaceuticals Reports that the European Commission has Granted Marketing Authorization for Zalviso for Treatment of Acute Moderate-to-Severe Post-Operative Pain in Adult Patients PR Newswire
Sep-21-15 07:00AM  PDL BioPharma Acquires a Portion of AcelRx Pharmaceuticals' Expected Royalties and Commercial Milestones from Zalviso for $65 Million PR Newswire
07:00AM  AcelRx Pharmaceuticals Receives $65 Million from the Partial Sale of Zalviso European Royalties and Commercial Milestones to PDL BioPharma PR Newswire
06:20AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition
Sep-10-15 08:34AM  Why You Shouldn't Bet Against AceIRx Pharmaceuticals (ACRX) Stock
Sep-09-15 02:35PM  ETFs with exposure to AcelRx Pharmaceuticals, Inc. : September 9, 2015
08:43AM  AcelRx Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : September 9, 2015
07:00AM  AcelRx Pharmaceuticals' ARX-04 Meets all Endpoints in Pivotal Phase 3 Study for Moderate-to-Severe Acute Pain PR Newswire
06:07AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Sep-08-15 06:05AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure
Sep-04-15 08:45AM  5 Analyst Stocks With Massive Upside Calls This Week at 24/7 Wall St.
Sep-02-15 11:18AM  3 Catalysts To Watch Over The Next Couple Months For This Pharma Co.
07:23AM  Coverage initiated on AcelRx by H.C. Wainwright
Aug-26-15 07:00AM  AcelRx Pharmaceuticals to Participate at Three Investor Conferences In September PR Newswire
Aug-21-15 04:11PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements an
08:32AM  Why AceIRx (ACRX) Could Be a Potential Winner
Aug-06-15 08:09PM  10-Q for AcelRx Pharmaceuticals, Inc. at Company Spotlight -7.02%
08:51AM  Concert Pharmaceuticals (CNCE) in Focus: Stock Rises 5.2% - Tale of the Tape
Aug-04-15 04:32PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits +9.88%
09:30AM  New Strong Buy Stocks for August 4th - Tale of the Tape
08:24AM  Edited Transcript of ACRX earnings conference call or presentation 3-Aug-15 8:30pm GMT
06:35AM  ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Aug-03-15 05:39PM  AcelRx Pharmaceuticals reports 2Q loss
04:30PM  AcelRx Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:01PM  AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results PR Newswire
07:07AM  Q2 2015 AcelRx Pharmaceuticals Inc Earnings Release - After Market Close
Jul-29-15 05:05PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
07:00AM  AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. PR Newswire
Jul-24-15 12:13PM  5 Stocks Poised for Breakouts at TheStreet
09:32AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  AcelRx Announces Positive CHMP Opinion for Zalviso in the Management of Acute Moderate-to-Severe Post-Operative Pain in Adult Patients PR Newswire
Jul-14-15 02:21PM  3 Stocks Under $10 to Trade for Breakouts at TheStreet +6.31%
Jul-02-15 07:00AM  Zalviso Phase 3 Orthopedic Results Published In Anesthesiology Demonstrate Significant Reductions In Post-Operative Pain PR Newswire
Jul-01-15 12:02PM  10 Worst Biotech Stocks in the NASDAQ at TheStreet
Jun-26-15 05:07AM  Edited Transcript of ACRX presentation 1-Jun-15 8:00pm GMT
Jun-24-15 04:39PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-03-15 08:45AM  Can the Rally in AcelRx Pharmaceuticals (ACRX) Shares Continue? - Tale of the Tape +13.08%
May-22-15 07:00AM  AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June PR Newswire
May-19-15 02:16PM  7 Biotech Stocks Moving Off The UBS Healthcare Conference +10.19%
May-15-15 09:52AM  AcelRx Pharmaceuticals (ACRX) Looks Good: Stock Up 8% - Tale of the Tape
May-14-15 12:00PM  AcelRX Takes Flight With New Department of Defense Contract at 24/7 Wall St. +7.97%
07:00AM  AcelRx Awarded Contract from Department of Defense to Advance ARX-04 PR Newswire
06:08AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
May-08-15 04:50PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
May-07-15 08:09PM  10-Q for AcelRx Pharmaceuticals, Inc. at Company Spotlight
May-06-15 04:40PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
May-05-15 08:12PM  10-K for AcelRx Pharmaceuticals, Inc. at Company Spotlight -27.74%
04:50PM  The 52-Week Low Club for Tuesday at 24/7 Wall St.
04:37PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
06:10AM  ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain. The company's lead product candidate is Zalviso, an investigational, pre-programmed, non-invasive, handheld system that has completed Phase III clinical trials for the treatment of moderate-to-severe acute pain in the hospital setting. The company is also developing ARX-04, a sufentanil single-dose tablet, which has been planned to initiate Phase III clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in settings of acute pain, such as in the emergency room, hospital floor, ambulatory care facilities, or on the battlefield. In addition, its product candidate pipeline consists of ARX-02, a pain management system that has completed Phase II clinical trials for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a single, fixed-dose, and combination drug product, which has been completed Phase II clinical trial designed to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLC10% OwnerNov 18Sale5.3542,300226,1325,995,760Nov 19 04:15 PM
PERCEPTIVE ADVISORS LLC10% OwnerNov 17Sale5.36133,900717,4096,038,060Nov 19 04:15 PM
PERCEPTIVE ADVISORS LLC10% OwnerNov 06Sale4.4717,10076,3656,171,960Nov 09 04:30 PM
PERCEPTIVE ADVISORS LLC10% OwnerNov 05Sale4.6275,000346,2606,189,060Nov 09 04:30 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 09Sale4.18310,0001,294,7776,264,060Sep 11 04:01 PM
EDWARDS MARK GDirectorMay 07Buy3.1340,000125,116100,000May 07 05:35 PM
Palmer Pamela PChief Medical OfficerMar 12Option Exercise1.3225,00033,000370,015Mar 17 03:58 PM